Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZKFU7)

• Drug Name: 4SCAR19 and 4SCAR38 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
B-cell lymphoma	2A86	Phase 1/2	[1]

• Cross-matching ID: TTD Drug ID: DMZKFU7

Molecule-Related Drug Atlas

Drug(s) Targeting Cyclic ADP-ribose hydrolase 1 (CD38)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Daratumumab	DMKCIUZ	Multiple myeloma	2A83	Approved	[2]
Mezagitamab	DMWJXFO	Myasthenia gravis	8C6Y	Phase 2	[3]
CD38 and BCMA CAR-T Cells	DMFZS8A	Multiple myeloma	2A83	Phase 1/2	[4]
ISB 1342	DMG107N	Multiple myeloma	2A83	Phase 1/2	[5]
Anti-CD38 CAR-T cells	DMTVXBY	Multiple myeloma	2A83	Phase 1/2	[6]
CD38 CAR T cells	DMPS3I6	Multiple myeloma	2A83	Phase 1/2	[7]
CD38 CAR-T Cell	DM0USBX	Acute lymphoblastic leukaemia	2A85	Phase 1/2	[8]
SAR-650984	DMD20YH	Haematological malignancy	2B33.Y	Phase 1/2	[9]
MOR-202	DMR8AHJ	Multiple myeloma	2A83	Phase 1/2	[10]
Anti-CD38 CAR-T cells	DMTVXBY	Multiple myeloma	2A83	Phase 1/2	[11]

Drug(s) Targeting B-lymphocyte surface antigen B4 (CD19)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tisagenlecleucel	DMM9BJD	Acute lymphoblastic leukaemia	2A85	Approved	[12]
Blinatumomab	DMGECIJ	Acute lymphoblastic leukaemia	2A85	Approved	[13]
Axicabtagene ciloleucel	DMYHN59	Diffuse large B-cell lymphoma	2A81	Approved	[14]
Lisocabtagene maraleucel	DMP45ME	Large B-cell lymphoma	2A81	Approved	[15]
Inebilizumab	DMI0RHA	Neuromyelitis optica spectrum disorder	8E4A.0	Approved	[16]
Tecartus	DMYQCWT	Mantle cell lymphoma	2A85.5	Approved	[17]
Loncastuximab tesirine	DMXSVGI	Diffuse large B-cell lymphoma	2A81	Approved	[18]
Obexelimab	DMVIC4J	IgG4 related disease	4A43.0	Phase 3	[19]
MOR-208	DMDQOWT	Diffuse large B-cell lymphoma	2A81	Phase 2/3	[20]
CART-19	DMST3FM	Acute lymphoblastic leukaemia	2A85	Phase 2/3	[21]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B-lymphocyte surface antigen B4 (CD19)	TTW640A	CD19_HUMAN	CAR-T-Cell-Therapy(Dual specific)	[1]
Cyclic ADP-ribose hydrolase 1 (CD38)	TTPURFN	CD38_HUMAN	CAR-T-Cell-Therapy(Dual specific)	[1]

References

• [1] ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
• [2] Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med. 2015 Sep 24;373(13):1207-19.
• [3] Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti-CD38 cytolytic antibody TAK-079 in healthy subjects. Br J Clin Pharmacol. 2020 Jul;86(7):1314-1325.
• [4] ClinicalTrials.gov (NCT03767751) A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma
• [5] Clinical pipeline report, company report or official report of Ichnos Sciences.
• [6] ClinicalTrials.gov (NCT03464916) Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients
• [7] ClinicalTrials.gov (NCT03271632) Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma
• [8] ClinicalTrials.gov (NCT03754764) A Feasibility and Safety Study of CD38 CAR-T Cell Immunotherapy for Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T Adoptive Cellular Immunotherapy
• [9] Clinical pipeline report, company report or official report of Sanofi-Aventis.
• [10] Clinical pipeline report, company report or official report of MorphoSys.
• [11] ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
• [12] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [13] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [14] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
• [15] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
• [16] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [17] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
• [18] Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2021 May 13;137(19):2634-2645.
• [19] Emerging B-Cell Therapies in Systemic Lupus Erythematosus. Ther Clin Risk Manag. 2021 Jan 14;17:39-54.
• [20] A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 2014 Dec 4;124(24):3553-60.
• [21] ClinicalTrials.gov (NCT03027739) CART-19 Cells For MRD Positive CD19+ ALL